UBS Group’s Janux Therapeutics JANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.76M | Sell |
292,533
-195,947
| -40% | -$4.53M | ﹤0.01% | 2795 |
|
|
2025
Q1 | $13.2M | Buy |
488,480
+263,390
| +117% | +$7.11M | ﹤0.01% | 2133 |
|
|
2024
Q4 | $12.1M | Buy |
225,090
+170,896
| +315% | +$9.15M | ﹤0.01% | 2176 |
|
|
2024
Q3 | $2.46M | Buy |
54,194
+3,326
| +7% | +$151K | ﹤0.01% | 2869 |
|
|
2024
Q2 | $2.13M | Buy |
50,868
+28,664
| +129% | +$1.2M | ﹤0.01% | 2802 |
|
|
2024
Q1 | $836K | Buy |
+22,204
| New | +$836K | ﹤0.01% | 3678 |
|
|
2023
Q2 | – | Sell |
-841
| Closed | -$10.2K | – | 8104 |
|
|
2023
Q1 | $10.2K | Buy |
841
+628
| +295% | +$7.6K | ﹤0.01% | 6508 |
|
|
2022
Q4 | $2.81K | Buy |
+213
| New | +$2.81K | ﹤0.01% | 8424 |
|
|
2022
Q2 | – | Sell |
-3,500
| Closed | -$50K | – | 9485 |
|
|
2022
Q1 | $50K | Sell |
3,500
-185
| -5% | -$2.64K | ﹤0.01% | 5474 |
|
|
2021
Q4 | $73K | Buy |
3,685
+185
| +5% | +$3.67K | ﹤0.01% | 5488 |
|
|
2021
Q3 | $76K | Buy |
3,500
+3,147
| +892% | +$68.3K | ﹤0.01% | 4943 |
|
|
2021
Q2 | $9K | Buy |
+353
| New | +$9K | ﹤0.01% | 7039 |
|